SCHEMBL15401504

SCHEMBL15401504

[2H]C1([2H])C(O)C([2H])([2H])C([2H])([2H])N(C(=O)OC(C)(C)C)C1([2H])[2H]

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NR1H2 P55055 1/20 0.42
HPGD P15428 1/20 0.41
RECQL P46063 1/20 0.40
EPHX1 P07099 1/20 0.40
EPHX2 P34913 1/20 0.38
GPR119 Q8TDV5 3/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17122072 0.87 USP2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL12236519 0.85 CHRM2 (0.50) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL15400955 0.85 USP2 (0.53) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL17122067 0.85 USP2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL17190705 0.84 USP2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL17122078 0.80 CHRM2 (0.49) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL16940802 0.80 CHRM2 (0.41) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL12604691 0.78 NR1H2 (0.41) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL12604688 0.78 NR1H2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL29558378 0.78 NR1H2 (0.41) CHRM2CHRM1CHRM3USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9707218-B2 Derivatives of pyrazole-substituted amino-heteroaryl compounds CONCERT PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-9707218-B2 Derivatives of pyrazole-substituted amino-heteroaryl compounds CONCERT PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-20150366853-A1 Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds CONCERT PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150366853-A1 Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds CONCERT PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150299170-A1 FLUORO-DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS CONCERT PHARMACEUTICALS INC (US) 2015-10-22 US disclosed
US-9145390-B2 Derivatives of pyrazole-substituted amino-heteroaryl compounds CONCERT PHARMACEUTICALS, INC. (US) 2015-09-29 US disclosed
US-9145390-B2 Derivatives of pyrazole-substituted amino-heteroaryl compounds CONCERT PHARMACEUTICALS, INC. (US) 2015-09-29 US disclosed
US-20140005211-A1 DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS CONCERT PHARMACEUTICALS, INC. (US) 2014-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299170-A1 FLUORO-DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS ALK, ABL1, BRAF CHRM2 4390/4885CHRM1 4693/4885CHRM3 3437/4885
US-20150366853-A1 Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds ALK, ABL1, MALT1 CHRM2 4449/4885CHRM1 4725/4885CHRM3 3725/4885
US-20140005211-A1 DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS ALK, ABL1, MALT1 CHRM2 4449/4885CHRM1 4725/4885CHRM3 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.